Cresco Labs Inc.
Cresco Labs is a U.S. cannabis operator licensed to cultivate, manufacture, and sell medical and retail cannabis products. It operates consolidated wholesale and retail segments, selling branded products through its Sunnyside dispensaries and wholesale to third-party retail stores. Its brands include Cresco, High Supply, Good News, Wonder Wellness Co., FloraCal, Remedi, Mindy’s, and Loud*r. Products include flower, vapes, pre-rolls, concentrates, edibles, and other forms. Cresco makes money by selling its manufactured cannabis products through company-owned and managed dispensaries and third-party dispensaries, and by selling bulk product. As of March 5, 2026, it operates 73 dispensaries across Illinois, Pennsylvania, Ohio, New York, Massachusetts, and Florida. Its cultivation and manufacturing operations span seven states. Cresco is headquartered in Chicago, Illinois.
No SEC Form 4 filings for $CRLBF in the last 30 days.
See all $CRLBF insider activity →Cresco Labs Inc. (CRLBF) furnished an SEC Form 6-K — earnings release. Cresco Labs Exhibit 99.3 Page 1 of 8 Cresco Labs Reports Third Quarter 2026 Financial Results Delivers $173 Million in Revenue and $26 Million Operating Cash Flow CHICAGO – November 6, 2026 – Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“ Cresco Labs ” or the “ Company ”
Cresco Labs reported Q3 2026 revenue of $173 million, a gross profit of $79 million, and a net loss of $15 million. The company generated $26 million in operating cash flow. Management highlighted preparedness for federal regulatory changes. As of September 30, 2026, Cresco Labs had $454 million in cash and $76 million in long-term debt.
Cresco Labs shareholders approved measures to streamline capital structure and governance, including creating a new parent company and potentially redomiciling to Delaware. They also elected seven directors. The company aims for a U.S. exchange listing, according to the press release.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning CRLBF (Cresco Labs Inc.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.
Recent CRLBF coverage spans earnings, corporate actions and market movers.
Earnings show modest growth and cash generation but a net loss, likely leading to limited price movement.
Cresco Labs reported Q3 2026 revenue of $173 million, a gross profit of $79 million, and a net loss of $15 million. The company generated $26 million in operating cash flow. Management highlighted preparedness for federal regulatory changes. As of September 30, 2026, Cresco Labs had $454 million in cash and $76 million in long-term debt.
Potential U.S. listing could increase liquidity and valuation.
Cresco Labs (CRLBF) shareholders will vote on a proposal to change shares with extra voting power on Oct. 30, 2026. The meeting will be held via live audio webcast, and shareholders of record as of Sept. 15, 2026, are entitled to vote. The company's management and directors may participate in the solicitation of proxies. Cresco Labs is a cannabis company focused on building national brands and operating dispensaries.
Cresco Labs reported Q2 2026 revenue of US$173.341 million, up from US$163.624 million in Q2 2025, and a profit of US$16.796 million, reversing a previous loss. Despite this, shares fell 54.2% over the past year. Analysts debated its future, with bulls citing margin improvement and bears highlighting competitive pressures. The company's stock now trades at CA$0.92.
AlphAI scores every news story that mentions CRLBF with an AI model for sentiment and relevance, and aggregates insider trades from Cresco Labs Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cresco Labs Inc. (CRLBF) furnished an SEC Form 6-K — earnings release. Cresco Labs Exhibit 99.3 Page 1 of 8 Cresco Labs Reports Third Quarter 2026 Financial Results Delivers $173 Million in Revenue and $26 Million Operating Cash Flow CHICAGO – November 6, 2026 – Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“ Cresco Labs ” or the “ Company ”
Cresco Labs reported Q3 2026 revenue of $173 million, a gross profit of $79 million, and a net loss of $15 million. The company generated $26 million in operating cash flow. Management highlighted preparedness for federal regulatory changes. As of September 30, 2026, Cresco Labs had $454 million in cash and $76 million in long-term debt.
Cresco Labs shareholders approved measures to streamline capital structure and governance, including creating a new parent company and potentially redomiciling to Delaware. They also elected seven directors. The company aims for a U.S. exchange listing, according to the press release.
Cresco Labs (CRLBF) shareholders will vote on a proposal to change shares with extra voting power on Oct. 30, 2026. The meeting will be held via live audio webcast, and shareholders of record as of Sept. 15, 2026, are entitled to vote. The company's management and directors may participate in the solicitation of proxies. Cresco Labs is a cannabis company focused on building national brands and operating dispensaries.
Cresco Labs reported Q2 2026 revenue of US$173.341 million, up from US$163.624 million in Q2 2025, and a profit of US$16.796 million, reversing a previous loss. Despite this, shares fell 54.2% over the past year. Analysts debated its future, with bulls citing margin improvement and bears highlighting competitive pressures. The company's stock now trades at CA$0.92.
Cresco Labs (CSE: CL, OTCQX: CRLBF, FSE: 6CQ) filed its Management Information Circular for its annual meeting on October 30, 2026. Shareholders will vote on proposals to streamline capital structure, redomicile to Delaware, and extend the sunset date for multiple voting shares, aiming for a U.S. exchange listing. The company seeks to simplify its structure and reduce administrative costs.
Cresco Labs Inc. (CSE: CL, OTCQX: CRLBF, FSE: 6CQ) appointed Edward Tilly, former CBOE Chairman and CEO, to its Board of Directors. Tilly brings over 35 years of experience in exchange operations and capital markets. He will serve as an independent director and join the Audit Committee, effective September 18, 2026. Tilly's expertise is expected to aid Cresco Labs as it navigates U.S. capital markets and legislative changes.
Cresco Labs (CRLBF) shares rose 10% in a month, driven by strong Q2 2026 results. Revenue increased 15% to $173M, with improved margins. Management expects Q3 revenue to be stable but margins to normalize. The company faces competition from peers like Verano (VRNO) and Curaleaf (CURLF). Analysts have mixed loss-per-share estimates for 2026 and 2027.
Simply Wall St reports Cresco Labs’ Q2 results shifted to profitability, with revenue of US$173.3m (vs. US$166.1m), net income of US$16.8m (vs. a US$16.3m loss), and basic EPS of US$0.045. Adjusted EBITDA was US$40m, with a 22.8% margin and 51.6% adjusted gross margin. Operating cash flow was US$15m vs capex US$9m, while management guided Q3 EBITDA margin near 20%.
Cresco Labs Inc. (OTCMKTS:CRLBF) shares rose 3.6% to $0.9498 after trading as high as $0.98 on Monday; the article says 476,660 shares changed hands, down 31% from average volume. Zacks upgraded the stock from “strong sell” to “hold.” For the quarter ended May 8, EPS was -$0.04 vs -$0.03 estimate on revenue of $151.33M vs $148.58M.
